MedTrace Logo

Photobiomodulation Therapy in the Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy

NCT05199389 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-03-06

No results posted yet for this study

Summary

This study aims to investigate the effectiveness of photobiomodulation therapy (PBM) in the management of chemotherapy-induced peripheral neuropathy (CIPN). Therefore, the hypothesis is that PBM can reduce the severity of CIPN in cancer patients, increasing the patient's quality of life.

Conditions

  • Chemotherapy-induced Peripheral Neuropathy

Interventions

DEVICE

Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)

MLS® Laser M6 is a PBM device that allows the patients to be treated in various positions, either sitting, lying down or at a distance, without risk of contamination. Treatment times are carefully calibrated to deliver the best possible energy dose to the tissue being treated.

Sponsors & Collaborators

  • Jessa Hospital

    lead OTHER

Principal Investigators

  • Jeroen Mebis, Prof. Dr. · Jessa Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-31
Primary Completion
2023-11-15
Completion
2028-11-10

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05199389 on ClinicalTrials.gov